UBS raised the firm’s price target on Boston Scientific (BSX) to $135 from $130 and keeps a Buy rating on the shares. Boston Scientific again exceeded expectations as the company continues to benefit from the most positive product cycle in all of large-cap MedTech, with an organic sales and EPS growth quarter above consensus, the analyst tells investors in a research note. Operational strength continues to drive outperformance, UBS adds.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BSX:
- Boston Scientific price target raised to $124 from $118 at Wells Fargo
- Boston Scientific price target raised to $133 from $125 at Barclays
- Boston Scientific Reports Strong Q2 2025 Results
- Boston Scientific Reports Strong Q2 Growth Amid Challenges
- Boston Scientific’s Strong Financial Performance and Positive Outlook Earns Buy Rating